摘要
目的对结核病患者氟喹诺酮类药物的药品不良反应(adverse drug reaction,ADR)报告进行分析,为临床合理应用提供参考。方法采用回顾性研究方法,对2013年1月1日至2020年6月30日期间我院结核病患者使用氟喹诺酮类药物发生ADR的病例进行调查并统计分析。结果共收到113例结核病患者氟喹诺酮类药物ADR报告,其中严重ADR占10.62%。涉及3种氟喹诺酮类药物,依次为左氧氟沙星、依诺沙星、莫西沙星。累及系统-器官主要为皮肤及附件损害、全身反应和胃肠系统等。静脉给药方式所致ADR多于口服。7.08%的患者存在不合理用药问题,表现为遴选药物不适宜。结论临床治疗过程中应该高度重视结核病患者氟喹诺酮类药物ADR的监测,发现ADR及时采取有效措施,提高用药的安全性。
Objective To analyse the adverse drug reactions(ADR)reports induced by fluoroquinolones in patients with tuberculosis,so as to provide reference for rational drug use.Methods The cases of ADR induced by fluoroquinolones in patients with tuberculosis from January 1,2013 to June 30,2020 in our hospital were retrospectively investigated and analyzed.Results A total of 113 cases of ADR of fluoroquinolones were reported in tuberculosis patients,of which serious ADR accounted for 10.62%.Three kinds of fluoroquinolones were involved,levofloxacin,enoxacin,and moxifloxacin in turn.Clinical manifestations involved skin and appendages disorders,systemic reaction,gastrointestinal system.ADR induced by intravenous administration was more than oral administration.7.08%of the patients had irrational drug use,which manifested as unsuitable selection of drugs.Conclusion The monitoring of ADR of fluoroquinolones in tuberculosis patients should be attached great importance in clinical treatment,and effective measures should be taken timely to improve the safety of drug use.
作者
朱娜
阚晓宏
吴欣俐
丁海华
薛淑雅
张云玲
ZHU Na;KAN Xiaohong;WU Xinli;DING Haihua;XUE Shuya;ZHANG Yunling(Department of Pharmacy,Anhui Chest Hospital,Hefei Anhui 230022,China;Department of Science and Education,Anhui Chest Hospital,Hefei Anhui 230022,China)
出处
《中国药物警戒》
2022年第4期404-407,共4页
Chinese Journal of Pharmacovigilance
基金
重大新药创制国家科技重大专项2018年度(2018ZX10722302-001-006)。
